Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo

被引：4

作者：

Fu, Cynthia H. Y. ^{[1
,2
]}

Antoniades, Mathilde ^{[3
]}

Erus, Guray ^{[3
]}

Garcia, Jose A. ^{[3
]}

Fan, Yong ^{[3
]}

Arnone, Danilo ^{[2
]}

Arnott, Stephen R. ^{[4
]}

Chen, Taolin ^{[5
,6
]}

Choi, Ki Sueng ^{[7
]}

Fatt, Cherise Chin ^{[8
]}

Frey, Benicio N. ^{[9
,10
]}

Frokjaer, Vibe G. ^{[11
,12
,13
]}

Ganz, Melanie ^{[11
,14
]}

Godlewska, Beata R. ^{[15
,16
]}

Hassel, Stefanie ^{[17
,18
]}

Ho, Keith ^{[19
]}

Mcintosh, Andrew M. ^{[20
]}

Qin, Kun ^{[5
,6
,21
]}

Rotzinger, Susan ^{[19
,22
]}

Sacchet, Matthew D. ^{[23
]}

Savitz, Jonathan ^{[24
]}

Shou, Haochang ^{[3
,25
]}

Singh, Ashish ^{[3
]}

Stolicyn, Aleks ^{[20
]}

Strigo, Irina ^{[26
]}

Strother, Stephen C. ^{[4
,27
]}

Tosun, Duygu ^{[28
]}

Victor, Teresa A. ^{[24
]}

Wei, Dongtao ^{[29
]}

Wise, Toby ^{[30
]}

Zahn, Roland ^{[2
]}

Anderson, Ian M. ^{[31
]}

Craighead, W. Edward ^{[32
,33
]}

Deakin, J. F. William ^{[31
]}

Dunlop, Boadie W. ^{[32
]}

Elliott, Rebecca ^{[31
]}

Gong, Qiyong ^{[5
,6
]}

Gotlib, Ian H. ^{[34
]}

Harmer, Catherine J. ^{[15
]}

Kennedy, Sidney H. ^{[19
,22
]}

Knudsen, Gitte M. ^{[11
,12
]}

Mayberg, Helen S. ^{[7
]}

Paulus, Martin P. ^{[24
]}

Qiu, Jiang ^{[29
]}

Trivedi, Madhukar H. ^{[8
]}

Whalley, Heather C. ^{[20
]}

Yan, Chao-Gan ^{[35
]}

Young, Allan H. ^{[2
,36
]}

Davatzikos, Christos ^{[3
]}

机构：

[1] Univ East London, Sch Psychol, London, England

[2] Kings Coll London, Ctr Affect Disorders, Dept Psychol Med, Inst Psychiat Psychol & Neurosci, London, England

[3] Univ Penn, Ctr Biomed Image Comp & Analyt, Perelman Sch Med, Philadelphia, PA 19104 USA

[4] Rotman Res Inst, Baycrest Ctr, Toronto, ON, Canada

[5] Sichuan Univ, West China Hosp, Huaxi MR Res Ctr, Dept Radiol, Chengdu, Peoples R China

[6] Chinese Acad Med Sci, Res Unit Psychoradiol, Chengdu, Peoples R China

[7] Icahn Sch Med Mt Sinai, Nash Family Ctr Adv Circuit Therapeut, New York, NY USA

[8] Univ Texas Southwestern Med Ctr, Ctr Depress Res & Clin Care, Dept Psychiat, Dallas, TX USA

[9] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada

[10] St Josephs Healthcare Hamilton, Mood Disorders Treatment & Res Ctr, Hamilton, ON, Canada

[11] Univ Hosp Rigshospitalet, Neurobiol Res Unit, Copenhagen, Denmark

[12] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark

[13] Psychiat Ctr Copenhagen, Dept Psychiat, Copenhagen, Denmark

[14] Univ Copenhagen, Dept Comp Sci, Copenhagen, Denmark

[15] Univ Oxford, Dept Psychiat, Oxford, England

[16] Warneford Hosp, Oxford Hlth NHS Fdn Trust, Oxford, England

[17] Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada

[18] Univ Calgary, Cumming Sch Med, Dept Psychiat, Calgary, AB, Canada

[19] Univ Hlth Network, Dept Psychiat, Toronto, ON, Canada

[20] Univ Edinburgh, Royal Edinburgh Hosp, Div Psychiat, Edinburgh, Scotland

[21] Hubei Univ Med, Taihe Hosp, Dept Radiol, Shiyan, Peoples R China

[22] Unity Hlth Toronto, Ctr Depress & Suicide Studies, Toronto, ON, Canada

[23] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Meditat Res Program, Boston, MA USA

[24] Laureate Inst Brain Res, Tulsa, OK USA

[25] Univ Penn, Penn Stat Imaging & Visualizat Endeavor PennS Ctr, Dept Biostat Epidemiol & Informat, Philadelphia, PA USA

[26] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA

[27] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada

[28] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA

[29] Southwest Univ, Sch Psychol, Chongqing, Peoples R China

[30] Kings Coll London, Dept Neuroimaging, Inst Psychiat Psychol & Neurosci, London, England

[31] Univ Manchester, Div Neurosci & Expt Psychol, Manchester, England

[32] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA

[33] Emory Univ, Dept Psychol, Atlanta, GA USA

[34] Stanford Univ, Dept Psychol, Stanford, CA USA

[35] Chinese Acad Sci, Inst Psychol, Key Lab Behav Sci, Beijing, Peoples R China

[36] South London & Maudsley NHS Fdn Trust, Bethlem Royal Hosp, London, England

来源：

NATURE MENTAL HEALTH | 2024年 / 2卷 / 02期

基金：

英国医学研究理事会; 英国惠康基金; 美国国家卫生研究院; 加拿大健康研究院; 中国国家自然科学基金;

关键词：

CORTICAL THICKNESS; CLINICAL-RESPONSE; DRUG-NAIVE; CONNECTIVITY; METAANALYSIS; BIOMARKERS; REGISTRATION; INFLAMMATION; ASSOCIATION; OUTCOMES;

D O I：

10.1038/s44220-023-00187-w

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Major depressive disorder (MDD) is a heterogeneous clinical syndrome with widespread subtle neuroanatomical correlates. Our objective was to identify the neuroanatomical dimensions that characterize MDD and predict treatment response to selective serotonin reuptake inhibitor (SSRI) antidepressants or placebo. In the COORDINATE-MDD consortium, raw MRI data were shared from international samples (N = 1,384) of medication-free individuals with first-episode and recurrent MDD (N = 685) in a current depressive episode of at least moderate severity, but not treatment-resistant depression, as well as healthy controls (N = 699). Prospective longitudinal data on treatment response were available for a subset of MDD individuals (N = 359). Treatments were either SSRI antidepressant medication (escitalopram, citalopram, sertraline) or placebo. Multi-center MRI data were harmonized, and HYDRA, a semi-supervised machine-learning clustering algorithm, was utilized to identify patterns in regional brain volumes that are associated with disease. MDD was optimally characterized by two neuroanatomical dimensions that exhibited distinct treatment responses to placebo and SSRI antidepressant medications. Dimension 1 was characterized by preserved gray and white matter (N = 290 MDD), whereas Dimension 2 was characterized by widespread subtle reductions in gray and white matter (N = 395 MDD) relative to healthy controls. Although there were no significant differences in age of onset, years of illness, number of episodes, or duration of current episode between dimensions, there was a significant interaction effect between dimensions and treatment response. Dimension 1 showed a significant improvement in depressive symptoms following treatment with SSRI medication (51.1%) but limited changes following placebo (28.6%). By contrast, Dimension 2 showed comparable improvements to either SSRI (46.9%) or placebo (42.2%) (beta = -18.3, 95% CI (-34.3 to -2.3), P = 0.03). Findings from this case-control study indicate that neuroimaging-based markers can help identify the disease-based dimensions that constitute MDD and predict treatment response.

引用

页码：164 / 176

页数：17

共 82 条

[1] Bostwick J.M., Pankratz V.S., Affective disorders and suicide risk: a reexamination, Am. J. Psychiatry, 157, pp. 1925-1932, (2000)
[2] James S.L., Et al., Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 392, pp. 1789-1858, (2018)
[3] Kessler R.C., The costs of depression, Psychiatr. Clin. North Am, 35, pp. 1-14, (2012)
[4] Vos T., Et al., Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, pp. 2163-2196, (2012)
[5] Rush A.J., The varied clinical presentations of major depressive disorder, J. Clin. Psychiatry, 68, pp. 4-10, (2007)
[6] Trivedi M.H., Et al., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice, Am. J. Psychiatry, 163, pp. 28-40, (2006)
[7] Chand G.B., Et al., Schizophrenia imaging signatures and their associations with cognition, psychopathology, and genetics in the general population, Am. J. Psychiatry, 179, pp. 650-660, (2022)
[8] Lalousis P.A., Et al., Neurobiologically based stratification of recent-onset depression and psychosis: identification of two distinct transdiagnostic phenotypes, Biol. Psychiatry, 92, pp. 552-562, (2022)
[9] Wen J., Et al., Characterizing heterogeneity in neuroimaging, cognition, clinical symptoms, and genetics among patients with late-life depression, JAMA Psychiatry, 79, pp. 464-474, (2022)
[10] Fu C.H.Y., Fan Y., Davatzikos C., Addressing heterogeneity (and homogeneity) in treatment mechanisms in depression and the potential to develop diagnostic and predictive biomarkers, Neuroimage Clin, 24, (2019)

← 1 2 3 4 5 6 7 8 9 →